ANDA 88631, held by Teva. Butabarbital Sodium.
As of Nov 16, 2026, ANDA 88631 (Butabarbital Sodium), held by Teva, was not approved, with 0 approved supplements and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| Butabarbital Sodium30MG ยท tablet;oral | Butabarbital Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters